Ceftazidime-Avibactam: Dosing, Indications, and Monitoring
Administer ceftazidime-avibactam 2.5 g IV every 8 hours infused over 3 hours for carbapenem-resistant Enterobacterales (CRE) infections, with dose adjustments required for renal impairment. 1
Primary Indications
Ceftazidime-avibactam is recommended for the following CRE infections:
Bloodstream Infections
- Dose: 2.5 g IV every 8 hours, infused over 3 hours
- Duration: 7-14 days 1
- Evidence level: Weak recommendation, low quality evidence (2D) 1
Complicated Urinary Tract Infections (cUTI)
- Dose: 2.5 g IV every 8 hours
- Duration: 5-7 days 1
- Evidence level: Weak recommendation, very low quality evidence (2D) 1
- Clinical trials demonstrated noninferiority to doripenem with 71.2% symptomatic resolution/microbiological eradication rates 2
Complicated Intra-Abdominal Infections (cIAI)
- Dose: 2.5 g IV every 8 hours plus metronidazole (for anaerobic coverage)
- Duration: 5-7 days 1
- Evidence level: Weak recommendation, very low quality evidence (2D) 1
Hospital-Acquired/Ventilator-Associated Pneumonia
- Approved by EMA for this indication 1
- Same dosing: 2.5 g IV every 8 hours
Difficult-to-Treat Pseudomonas aeruginosa (DTR-PA)
- Dose: 2.5 g IV every 8 hours
- Duration: 10-14 days for pneumonia/BSI; 5-10 days for cUTI/cIAI 1
- Evidence level: Weak recommendation, low quality evidence (2C) 1
Renal Dose Adjustments
Critical consideration: Dosing must be adjusted based on creatinine clearance (CrCl) to prevent both treatment failure and neurotoxicity 3, 4, 5.
Standard Renal Adjustments
While specific adjustment tables are referenced in the FDA label 3, recent evidence shows:
- CrCl >50 mL/min: Standard dose 2.5 g IV every 8 hours
- CrCl 30-50 mL/min: Reduced dose required (specific adjustments per FDA label) 3
- CrCl <30 mL/min: Further dose reduction necessary 3
Special Populations
Continuous Renal Replacement Therapy (CRRT):
- Standard dosing (2.5 g every 8 hours) may cause excessive drug exposure 5
- CRRT significantly reduces clearance: CAZ clearance 2.46 L/h during CVVH vs 0.9 L/h without 6
- 90.48% of CRRT patients exceeded neurotoxicity threshold (>104 mg/L) with standard dosing 5
- Recommendation: Dose reduction required; therapeutic drug monitoring (TDM) strongly advised 5
Augmented Renal Clearance (ARC) in ICU:
- Critically ill patients with preserved renal function may require higher doses (up to 12 g/day ceftazidime has been proposed) 7
- Standard dosing may be insufficient for bacteria with MIC ≥8 mg/L 8, 9
Administration Details
Infusion Parameters
- Infusion time: 3 hours (extended infusion) 1
- Extended infusion improves PK/PD target attainment, particularly for high-MIC pathogens 10
- Prolonged infusion associated with improved 30-day survival 10
PK/PD Targets
- Ceftazidime: 100% fT > MIC (time above MIC)
- Avibactam: 100% fT > 1.0-2.5 mg/L threshold concentration 8, 6
- Optimal target: fCmin/MIC ratio >4-8 for maximal bacterial killing 7
Monitoring Parameters
Baseline Assessment
- Creatinine clearance calculation (Cockcroft-Gault equation) 9
- Baseline renal function tests
- Neurological status assessment 7
Ongoing Monitoring
Renal Function:
- Monitor serum creatinine every 2-3 days
- Acute kidney injury (AKI) occurs more frequently in real-world use than clinical trials 4
- Higher risk with concomitant nephrotoxic agents 4
Neurotoxicity Risk:
- Critical threshold: Ceftazidime Cmin >80-104 mg/L associated with neurological toxicity 7, 11, 5
- Risk increases when fCmin/MIC ratio exceeds 8 7
- Monitor for confusion, encephalopathy, seizures (especially in renal impairment)
- Ceftazidime has relatively low pro-convulsive activity (17% relative to penicillin G) 7
Therapeutic Drug Monitoring (TDM):
- Strongly recommended in critically ill patients 8, 9
- Essential in patients receiving CRRT 5
- Consider in patients with ARC or fluctuating renal function 9
- Target trough concentrations: CAZ >20 mg/L, AVI >4 mg/L 12
Clinical Response
Important Caveats
Resistance Development
- Critical warning: Resistance can emerge during therapy, particularly with KPC-3 producers 1
- "See-saw effect": KPC-3 mutations increase ceftazidime-avibactam MIC while decreasing meropenem MIC 1
- Risk factors: Prior ceftazidime-avibactam exposure, prolonged therapy 1
- British Society for Antimicrobial Chemotherapy suggests considering combination with carbapenem or colistin for KPC-3 producers 1
Combination Therapy
- Monotherapy is standard for most CRE infections 10
- Combination therapy not routinely recommended based on current evidence 1, 10
- Exception: For MBL-producing CRE, combine with aztreonam (ceftazidime-avibactam alone is inactive against MBLs) 10, 11
Metallo-β-Lactamase (MBL) Producers
- Ceftazidime-avibactam inactive against MBL-producing CRE 1
- Solution: Co-administration with aztreonam restores activity 10, 11
- Requires simultaneous delivery and harmonized renal dose adjustments 11
Decreased Clinical Response
- Adult cIAI patients with baseline CrCl 30-50 mL/min showed decreased clinical response in trials 3
- Consider alternative therapy or enhanced monitoring in this population
Drug Interactions
- Probenecid: Increases ceftazidime exposure by blocking renal tubular secretion 3
- Avoid concomitant nephrotoxic agents when possible 4
Treatment Duration Summary
| Infection Type | Duration |
|---|---|
| Complicated UTI/Pyelonephritis | 5-7 days |
| Complicated Intra-abdominal | 5-7 days |
| Bloodstream infection | 7-14 days |
| Hospital/Ventilator pneumonia | 10-14 days |
Duration should be individualized based on infection site, source control, underlying comorbidities, and clinical response 1.